Pharmacokinetic and pharmacodynamic studies of pregabalin suppositories based on pharmacological research

Ryo Yajima, Kazuaki Matsumoto, Kanako Yokono, Yuki Watabe, Yuki Enoki, Kazuaki Taguchi, Yuya Ise, Shiro Katayama, Junko Kizu

Research output: Contribution to journalArticle

Abstract

Objectives: As commercially available pregabalin preparations are limited to oral administration, it is impossible to use it as an adjuvant analgesic for neuropathic cancer-related pain in terminally ill cancer patients with oral feeding difficulties. The objective of this study was to develop a pregabalin suppository to be available at hospitals. Methods: Pregabalin suppositories were prepared using bases comprising six different compositions of Witepsol H-15, Witepsol S-55, and Witepsol E-75. The suppository release test and stability test were performed in vitro. The pharmacokinetics and pharmacodynamics of the suppositories were assessed in rats. Key findings: In the in vitro releasing test, the pregabalin suppositories with H-15, H-15 : S-55 = 1 : 1, H-15 : S-55 = 2 : 1, H-15 : S-55 = 1 : 2 released approximately 100% of the pregabalin within 180 min. Among these pregabalin suppositories, only the suppository with H-15 : S-55 = 2 : 1 demonstrated an equivalent AUC0−∞ with the oral administration group. Consistent with the results of the pharmacokinetic study, the pregabalin suppository with H-15 : S-55 = 2 : 1 exhibited antinociceptive effects. In addition, the pregabalin suppository with H-15 : S-55 = 2 : 1 was stable for 12 weeks when refrigerated with light shielding. Conclusions: The pregabalin suppositories prepared in this study may be applicable for pain control for terminally cancer ill patients with oral feeding difficulties.

Original languageEnglish
JournalJournal of Pharmacy and Pharmacology
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Suppositories
Pharmacokinetics
Pharmacology
Research
Terminally Ill
Oral Administration
Pregabalin
Neuralgia
Analgesics
Neoplasms
Light
Pain

Keywords

  • pharmacokinetics
  • pregabalin
  • release test
  • suppository
  • tail-flick test

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Pharmacokinetic and pharmacodynamic studies of pregabalin suppositories based on pharmacological research. / Yajima, Ryo; Matsumoto, Kazuaki; Yokono, Kanako; Watabe, Yuki; Enoki, Yuki; Taguchi, Kazuaki; Ise, Yuya; Katayama, Shiro; Kizu, Junko.

In: Journal of Pharmacy and Pharmacology, 01.01.2018.

Research output: Contribution to journalArticle

Yajima, Ryo ; Matsumoto, Kazuaki ; Yokono, Kanako ; Watabe, Yuki ; Enoki, Yuki ; Taguchi, Kazuaki ; Ise, Yuya ; Katayama, Shiro ; Kizu, Junko. / Pharmacokinetic and pharmacodynamic studies of pregabalin suppositories based on pharmacological research. In: Journal of Pharmacy and Pharmacology. 2018.
@article{11416594059e417f86ec0fbae0dca128,
title = "Pharmacokinetic and pharmacodynamic studies of pregabalin suppositories based on pharmacological research",
abstract = "Objectives: As commercially available pregabalin preparations are limited to oral administration, it is impossible to use it as an adjuvant analgesic for neuropathic cancer-related pain in terminally ill cancer patients with oral feeding difficulties. The objective of this study was to develop a pregabalin suppository to be available at hospitals. Methods: Pregabalin suppositories were prepared using bases comprising six different compositions of Witepsol H-15, Witepsol S-55, and Witepsol E-75. The suppository release test and stability test were performed in vitro. The pharmacokinetics and pharmacodynamics of the suppositories were assessed in rats. Key findings: In the in vitro releasing test, the pregabalin suppositories with H-15, H-15 : S-55 = 1 : 1, H-15 : S-55 = 2 : 1, H-15 : S-55 = 1 : 2 released approximately 100{\%} of the pregabalin within 180 min. Among these pregabalin suppositories, only the suppository with H-15 : S-55 = 2 : 1 demonstrated an equivalent AUC0−∞ with the oral administration group. Consistent with the results of the pharmacokinetic study, the pregabalin suppository with H-15 : S-55 = 2 : 1 exhibited antinociceptive effects. In addition, the pregabalin suppository with H-15 : S-55 = 2 : 1 was stable for 12 weeks when refrigerated with light shielding. Conclusions: The pregabalin suppositories prepared in this study may be applicable for pain control for terminally cancer ill patients with oral feeding difficulties.",
keywords = "pharmacokinetics, pregabalin, release test, suppository, tail-flick test",
author = "Ryo Yajima and Kazuaki Matsumoto and Kanako Yokono and Yuki Watabe and Yuki Enoki and Kazuaki Taguchi and Yuya Ise and Shiro Katayama and Junko Kizu",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/jphp.13051",
language = "English",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",

}

TY - JOUR

T1 - Pharmacokinetic and pharmacodynamic studies of pregabalin suppositories based on pharmacological research

AU - Yajima, Ryo

AU - Matsumoto, Kazuaki

AU - Yokono, Kanako

AU - Watabe, Yuki

AU - Enoki, Yuki

AU - Taguchi, Kazuaki

AU - Ise, Yuya

AU - Katayama, Shiro

AU - Kizu, Junko

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: As commercially available pregabalin preparations are limited to oral administration, it is impossible to use it as an adjuvant analgesic for neuropathic cancer-related pain in terminally ill cancer patients with oral feeding difficulties. The objective of this study was to develop a pregabalin suppository to be available at hospitals. Methods: Pregabalin suppositories were prepared using bases comprising six different compositions of Witepsol H-15, Witepsol S-55, and Witepsol E-75. The suppository release test and stability test were performed in vitro. The pharmacokinetics and pharmacodynamics of the suppositories were assessed in rats. Key findings: In the in vitro releasing test, the pregabalin suppositories with H-15, H-15 : S-55 = 1 : 1, H-15 : S-55 = 2 : 1, H-15 : S-55 = 1 : 2 released approximately 100% of the pregabalin within 180 min. Among these pregabalin suppositories, only the suppository with H-15 : S-55 = 2 : 1 demonstrated an equivalent AUC0−∞ with the oral administration group. Consistent with the results of the pharmacokinetic study, the pregabalin suppository with H-15 : S-55 = 2 : 1 exhibited antinociceptive effects. In addition, the pregabalin suppository with H-15 : S-55 = 2 : 1 was stable for 12 weeks when refrigerated with light shielding. Conclusions: The pregabalin suppositories prepared in this study may be applicable for pain control for terminally cancer ill patients with oral feeding difficulties.

AB - Objectives: As commercially available pregabalin preparations are limited to oral administration, it is impossible to use it as an adjuvant analgesic for neuropathic cancer-related pain in terminally ill cancer patients with oral feeding difficulties. The objective of this study was to develop a pregabalin suppository to be available at hospitals. Methods: Pregabalin suppositories were prepared using bases comprising six different compositions of Witepsol H-15, Witepsol S-55, and Witepsol E-75. The suppository release test and stability test were performed in vitro. The pharmacokinetics and pharmacodynamics of the suppositories were assessed in rats. Key findings: In the in vitro releasing test, the pregabalin suppositories with H-15, H-15 : S-55 = 1 : 1, H-15 : S-55 = 2 : 1, H-15 : S-55 = 1 : 2 released approximately 100% of the pregabalin within 180 min. Among these pregabalin suppositories, only the suppository with H-15 : S-55 = 2 : 1 demonstrated an equivalent AUC0−∞ with the oral administration group. Consistent with the results of the pharmacokinetic study, the pregabalin suppository with H-15 : S-55 = 2 : 1 exhibited antinociceptive effects. In addition, the pregabalin suppository with H-15 : S-55 = 2 : 1 was stable for 12 weeks when refrigerated with light shielding. Conclusions: The pregabalin suppositories prepared in this study may be applicable for pain control for terminally cancer ill patients with oral feeding difficulties.

KW - pharmacokinetics

KW - pregabalin

KW - release test

KW - suppository

KW - tail-flick test

UR - http://www.scopus.com/inward/record.url?scp=85057959934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057959934&partnerID=8YFLogxK

U2 - 10.1111/jphp.13051

DO - 10.1111/jphp.13051

M3 - Article

C2 - 30515815

AN - SCOPUS:85057959934

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

ER -